Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer with Mediastinal Lymph Node Involvement

Brandon Tieu, Rachel E. Sanborn, Charles Thomas

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Survival outcomes of patients with stage IIIA non-small cell lung cancer (NSCLC) with mediastinal lymph node involvement (N2 disease) have been poor when treated with surgery alone. Numerous studies have investigated induction chemotherapy, radiation, and chemoradiation to attempt to improve outcome in this high-risk population. The appropriate application and sequence of these treatments is still the subject of ongoing study. Surgical resection appears to have the greatest benefit in patients who have decreased mediastinal involvement following induction therapy, although the type of surgical resection (pneumonectomy or lesser resection) impacts morbidity and mortality risks after induction therapy. Molecularly targeted agents are also being studied as a potential induction therapy for use in the treatment of stage IIIA disease.

Original languageEnglish (US)
Pages (from-to)403-415
Number of pages13
JournalThoracic Surgery Clinics
Volume18
Issue number4
DOIs
StatePublished - Nov 2008

Fingerprint

Neoadjuvant Therapy
Non-Small Cell Lung Carcinoma
Lymph Nodes
Therapeutics
Induction Chemotherapy
Pneumonectomy
Radiation
Morbidity
Survival
Mortality
Population

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer with Mediastinal Lymph Node Involvement. / Tieu, Brandon; Sanborn, Rachel E.; Thomas, Charles.

In: Thoracic Surgery Clinics, Vol. 18, No. 4, 11.2008, p. 403-415.

Research output: Contribution to journalArticle

@article{2ec2537564e047a39676bad74a7f0b80,
title = "Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer with Mediastinal Lymph Node Involvement",
abstract = "Survival outcomes of patients with stage IIIA non-small cell lung cancer (NSCLC) with mediastinal lymph node involvement (N2 disease) have been poor when treated with surgery alone. Numerous studies have investigated induction chemotherapy, radiation, and chemoradiation to attempt to improve outcome in this high-risk population. The appropriate application and sequence of these treatments is still the subject of ongoing study. Surgical resection appears to have the greatest benefit in patients who have decreased mediastinal involvement following induction therapy, although the type of surgical resection (pneumonectomy or lesser resection) impacts morbidity and mortality risks after induction therapy. Molecularly targeted agents are also being studied as a potential induction therapy for use in the treatment of stage IIIA disease.",
author = "Brandon Tieu and Sanborn, {Rachel E.} and Charles Thomas",
year = "2008",
month = "11",
doi = "10.1016/j.thorsurg.2008.07.004",
language = "English (US)",
volume = "18",
pages = "403--415",
journal = "Thoracic Surgery Clinics",
issn = "1547-4127",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer with Mediastinal Lymph Node Involvement

AU - Tieu, Brandon

AU - Sanborn, Rachel E.

AU - Thomas, Charles

PY - 2008/11

Y1 - 2008/11

N2 - Survival outcomes of patients with stage IIIA non-small cell lung cancer (NSCLC) with mediastinal lymph node involvement (N2 disease) have been poor when treated with surgery alone. Numerous studies have investigated induction chemotherapy, radiation, and chemoradiation to attempt to improve outcome in this high-risk population. The appropriate application and sequence of these treatments is still the subject of ongoing study. Surgical resection appears to have the greatest benefit in patients who have decreased mediastinal involvement following induction therapy, although the type of surgical resection (pneumonectomy or lesser resection) impacts morbidity and mortality risks after induction therapy. Molecularly targeted agents are also being studied as a potential induction therapy for use in the treatment of stage IIIA disease.

AB - Survival outcomes of patients with stage IIIA non-small cell lung cancer (NSCLC) with mediastinal lymph node involvement (N2 disease) have been poor when treated with surgery alone. Numerous studies have investigated induction chemotherapy, radiation, and chemoradiation to attempt to improve outcome in this high-risk population. The appropriate application and sequence of these treatments is still the subject of ongoing study. Surgical resection appears to have the greatest benefit in patients who have decreased mediastinal involvement following induction therapy, although the type of surgical resection (pneumonectomy or lesser resection) impacts morbidity and mortality risks after induction therapy. Molecularly targeted agents are also being studied as a potential induction therapy for use in the treatment of stage IIIA disease.

UR - http://www.scopus.com/inward/record.url?scp=53649097712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53649097712&partnerID=8YFLogxK

U2 - 10.1016/j.thorsurg.2008.07.004

DO - 10.1016/j.thorsurg.2008.07.004

M3 - Article

C2 - 19086609

AN - SCOPUS:53649097712

VL - 18

SP - 403

EP - 415

JO - Thoracic Surgery Clinics

JF - Thoracic Surgery Clinics

SN - 1547-4127

IS - 4

ER -